Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Software Development

14 Feb 2008 07:01

Angle PLC14 February 2008 For Immediate Release 14 February 2008 ANGLE plc Software Development Kit Launched by Geomerics ANGLE plc is pleased to announce that its venture company Geomerics hascompleted its Software Development Kit (SDK) for Enlighten, the revolutionaryradiosity lighting engine for PLAYSTATION(R)3, the Xbox 360(TM) entertainmentsystem from Microsoft and PC. Enlighten's SDK comprises a modular toolkit withan emphasis on easy integration into existing development frameworks. It alsoboasts intuitive operation designed with artists in mind and full support forindustry standard packages such as 3D Studio Max and Maya for maximumoperability. Enlighten's radiosity solution represents a generational step in videogamegraphics technology, surpassing all currently popular lighting techniques.Radiosity is the ability to model light as it bounces from surfaces and it iskey to generating high quality visual images. Current technologies forgenerating radiosity lighting involve either pre-computing it in advance, orfaking it with multiple hidden lights. These methods are typically inflexible,time-consuming and often generate poor results. Enlighten computes full multiple-bounce radiosity at runtime, giving developersthe quality of pre-computed lighting without the pre-compute. In-game lightingcan also be fully dynamic, giving designers a powerful new tool with hugepotential for enhancing the atmosphere and mood of any scene. Additionally,Enlighten's instantaneous feedback means that artists are freed up to experimentwith light, shadow and colour in dramatic new ways - just as if they were usingreal lights on a studio set. Gary Lewis, CEO, Geomerics comments: "We are delighted to be announcing the launch of the Enlighten SDK. With our SDKcompleted, we are looking forward to seeing Enlighten gaining the support itdeserves within the games industry. We are certain that once developers gettheir hands on the SDK and experiment with it for themselves, they will see thetrue power and versatility of Enlighten and the huge potential it has forrevolutionising the look of videogames for years to come." Geomerics will be at Expo Suite 561 throughout GDC Expo 2008, which runs from20th to the 22nd February. To book a meeting please contact: info@geomerics.com Enlighten is available for licensing for PC, Xbox 360 and Playstation 3. Formore information please contact: sales@geomerics.com Enquiries: ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications 0207 466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Angle plc Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE has a 48% equity holding in Geomerics Ltd.ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com Geomerics Ltd Geomerics is an innovation-led company specialising in graphics software for thegames industry and beyond. It is built on a combination of advanced in-house IP,a remarkable research team, and strong management experience. The company'sfirst product is Enlighten. Enlighten radically transforms the way that lightingis handled in computer games. Instead of pre-baking the effects of globalillumination into the scene they can now be computed at run time, allowing forfully dynamic lighting. This dramatically enhances realism as well as opening upa new world of creative possibilities for designers and artists. Further information can be found on www.geomerics.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.